Who founded Cadrenal Therapeutics?

Cadrenal Therapeutics was founded by Quang X. Pham in 2022.

How much funding has Cadrenal Therapeutics raised?

Cadrenal Therapeutics has disclosed $38.5M raised across 7 rounds.

Where is Cadrenal Therapeutics headquartered?

Cadrenal Therapeutics is headquartered in Ponte Vedra, US.

Cadrenal Therapeutics

NASDAQ: CVKD

Ponte Vedra, US · Founded 2022 · Delaware corporation

Find your way into Cadrenal Therapeutics

1,424 people in our graph share verified history with the Cadrenal Therapeutics team — schools, employers, funds. One of them is your warm intro.

Deep Nisharunlockedknows Matthew Szot · together at University of Illinois Urbana-Champaign (overlapped)

×5knows the team · via Stanford University

×2knows the team · via University of Illinois Urbana-Champaign

knows the team · via University of Pennsylvania School of Medicine

×3knows the team · via Case Western Reserve University

Cadrenal Therapeutics is a clinical-stage biopharmaceutical company developing anticoagulation and antithrombotic therapies for cardiovascular and thrombotic disorders. Its pipeline includes CAD-1005, a first-in-class 12-LOX inhibitor for heparin-induced thrombocytopenia, tecarfarin for end-stage kidney disease and LVAD patients, and frunexian, an intravenous Factor XIa inhibitor for acute/critical care settings.</parameter> <parameter name="founders">[]

Biotech Healthtech Medical Devices

Founders & leadership

Cadrenal Therapeutics was founded in 2022 by Quang X. Pham.

Quang X. Pham inFounder · Chairman, Chief Executive Officer & Chief Business OfficerCo-founder of hypergro.ai who previously worked at Glance in partnerships, content, and campaigns, including collaborations with CSK, Sony Music, Warner, and Femina Miss India.

Jeff ColeinChief Operating Officer

Matthew Szot inChief Financial Officer & Co-Founder2022–2026Matthew Szot is an executive with over 25 years of experience in finance and corporate leadership, having served as CFO at multiple companies where he led IPO preparations and Nasdaq listings, managed hundreds of millions in equity and debt financings, and oversaw numerous mergers and acquisitions across life sciences, healthcare, and other industries. He currently serves as Board Chair of SenesTech and Director of INVO Fertility.

Douglas W. Losordo inChief Medical Officer2023–2025Douglas W. Losordo is an executive officer at Cadrenal Therapeutics, a clinical-stage biopharmaceutical company developing anticoagulation and antithrombotic therapies for cardiovascular and thrombotic disorders. He has a background as a physician and scientist focused on therapeutic development.

John P. SharpInterim Chief Financial Officer

James J. Ferguson inChief Medical OfficerJames J. Ferguson is Chief Medical Officer at Cadrenal Therapeutics. He has worked as a senior scientist in small molecule drug discovery at biotech companies, with experience in assay development, mechanism of action studies, and in vivo research in muscular dystrophy, pulmonary fibrosis, and cancer models.

Terry Ferguson inChief Medical Officer2025–2026Terry Ferguson brings over 15 years of pharmaceutical industry leadership experience, with background in clinical development, regulatory affairs, and medical affairs across both large and small organizations, and has held academic and clinical trial roles.

James J. Ferguson IIIChief Medical Officer

Board

Steven ZelenkofskeBoard director

John R. MurphyBoard director

Glynn WilsonBoard director

Robert LisickiBoard director

Reported raises · per SEC filings

Form D private placements

$38.5M disclosed across 7 rounds · 2022–2026

▶$8.8MraisedJul 2026 · 1 investors · Biotechnology

Rule 506(b)